Please assess the completion status of the following clinical trial:

Trial Title: Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~Patients must meet all of the following criteria to be eligible for enrollment in the study.~* Histologically confirmed diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma American Joint Committee on Cancer Stage IIIB, IIIC, or IV.~* Presence of BRAF V600E or V600K mutation in tumor tissue as determined by a local or central laboratory~* Adequate cardiac function:~  * Left ventricular ejection fraction (LVEF) ≥ 50% as determined by ECHO or multi-gated acquisition (MUGA) scan and above the institutional lower limit of normal (LLN);~ * Triplicate average baseline QTcF value ≤ 450 ms.~* Adequate bone marrow, organ function, and laboratory parameters:~  * Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;~ * Hemoglobin ≥ 9 g/dL with or without transfusions;~ * Platelets ≥ 75 × 10⁹/L without transfusions;~ * Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); in patients with liver metastases ≤ 5 × ULN;~ * Total bilirubin ≤ 1.5 × ULN;~ * Creatinine ≤ 1.5 × institutional ULN for age, or calculated creatinine clearance ≥ 70 mL/min/1.73 m² (following Schwartz formula).~* Adequate performance status at Screening:~  * Patients \< 16 years old: Lansky Performance Scale score ≥ 80~ * Patients 16 to 17 years old: Karnofsky Performance Scale score ≥ 80~Key Exclusion Criteria:~Patients meeting any of the following criteria are not eligible for enrollment in the study.~* Uveal or mucosal melanoma.~* Brain metastases that are uncontrolled or symptomatic, require steroids, are potentially life-threatening or have required radiation within 28 days prior to starting study drug.~* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO~* Prior therapy with a BRAF inhibitor (e.g., dabrafenib, vemurafenib) and/or a MEK inhibitor (e.g., trametinib, cobimetinib).~* Impaired cardiovascular function or clinically significant cardiovascular disease, including any of the following:~  * History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stenting) \< 6 months prior to screening,~ * Symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality \< 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia.~* Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)~* Uncontrolled arterial hypertension despite medical treatment~* Presence of BRAFʷͭ or indeterminate melanoma in tumor tissue.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Safety Run-in Phase (Type: EXPERIMENTAL): * binimetinib taken twice daily (BID) and~* encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules are specified in the protocol.
- Expansion Phase (Type: EXPERIMENTAL): * binimetinib taken twice daily (BID) and~* encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules and pediatric formulations are specified in the protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).